The estimated Net Worth of Yakob Liawatidewi is at least 7.55 百万$ dollars as of 28 August 2023. Yakob Liawatidewi owns over 28,816 units of Amphastar Pharmaceuticals Inc stock worth over 4,438,719$ and over the last 6 years Yakob sold AMPH stock worth over 3,107,221$.
Yakob has made over 22 trades of the Amphastar Pharmaceuticals Inc stock since 2018, according to the Form 4 filled with the SEC. Most recently Yakob exercised 28,816 units of AMPH stock worth 428,206$ on 28 August 2023.
The largest trade Yakob's ever made was selling 31,524 units of Amphastar Pharmaceuticals Inc stock on 15 July 2021 worth over 630,795$. On average, Yakob trades about 5,503 units every 38 days since 2018. As of 28 August 2023 Yakob still owns at least 98,485 units of Amphastar Pharmaceuticals Inc stock.
You can see the complete history of Yakob Liawatidewi stock trades at the bottom of the page.
Yakob's mailing address filed with the SEC is C/O AMPHASTAR PHARMACEUTICALS, INC., 11570 6TH STREET, RANCHO CUCAMONGA, CA, 91730.
Over the last 10 years, insiders at Amphastar Pharmaceuticals Inc have traded over 72,457,295$ worth of Amphastar Pharmaceuticals Inc stock and bought 66,100 units worth 921,987$ . The most active insiders traders include Jack Y.Luo Mary Z. Zhang、Richard K Prins、William J Peters. On average, Amphastar Pharmaceuticals Inc executives and independent directors trade stock every 11 days with the average trade being worth of 1,459,051$. The most recent stock trade was executed by Floyd F. Petersen on 5 September 2024, trading 3,000 units of AMPH stock currently worth 139,410$.
amphastar pharmaceuticals, inc., headquartered in rancho cucamonga, california, established in 1996, is a recognized specialty pharmaceutical company that uses state-of-the-art, cgmp compliant facilities to develop, manufacture, and market injectable and inhalation products. in addition to the corporate headquarters, amphastar has five manufacturing facilities located in the united states, china and europe along with a state-of-the-art new drug research center. amphastar and its subsidiaries each have their own distinct focus that they skillfully bring together to meet the varied needs of the pharmaceutical industry. we currently produce approximately 15 injectable products while we continue to develop a portfolio of generic and branded products that target large markets with high technical barriers to entry. amphastar’s long-standing relationship with the major group purchasing organizations and drug wholesalers in the u.s. enables it to establish significant market share upon the int
Amphastar Pharmaceuticals Inc executives and other stock owners filed with the SEC include: